BMRA

Business Context and Reporting Period

Company: Biomerica, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2011 (First Quarter of Fiscal 2012)
Business Overview: Biomerica develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases. Products are sold to clinical laboratories and point-of-care settings (physicians' offices and drugstores) globally. The company maintains manufacturing operations in Irvine, California, and Mexicali, Mexico.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased by 19.5% ($229,953) compared to the prior year quarter. This was driven primarily by a significant increase in sales to Asia ($631,000 vs. $225,000), which offset a decline in U.S. sales ($187,000 vs. $303,000) attributed to higher initial purchasing volumes in the prior year.
• Profitability Turnaround: The company returned to profitability, reporting net income of $117,792 compared to a net loss of $12,186 in the prior year. Operating income improved from a loss of $12,230 to a profit of $116,901.
• Margin Expansion: Gross margin improved to 36.7% from 33.0%. This was due to a higher proportion of fixed costs relative to increased revenue and a shift toward higher-margin products. The prior year included a $56,458 bulk sales incentive (free product) that inflated costs.
• Expense Management: Research and development expenses decreased by 12.2% ($11,916) following the elimination of a dedicated R&D department in favor of licensing technology. Selling, general, and administrative (SG&A) expenses increased slightly by 3.4% primarily due to a higher bad debt reserve.
• Cash Flow: Operating cash flow turned positive, providing $108,024 compared to a use of $199,153 in the prior year. This improvement was aided by funds received under the Therapeutic Drug Recovery Act ($140,400 net of consulting fees).

Outlook, Risks, and Contingencies

• Capital Resources: The company maintains a $400,000 line of credit with Union Bank, which was renewed in June 2011 and expires in February 2012. The balance was zero as of August 31, 2011. An equipment loan of $23,664 remains outstanding.
• Customer Concentration: Two customers represented significant portions of gross receivables as of August 31, 2011: one at 42.3% and another at 11.2%. Management monitors these balances closely.
• Strategic Shift: The company eliminated its dedicated research department in July 2010 to focus on licensing technology. R&D costs are now allocated from production wages for technology transfer projects.
• Risk Factors: Key risks include macroeconomic downturns, dependence on international distributors, potential disruptions in raw material supply or shipping, regulatory approval delays, and competition from larger entities. The company is a "smaller reporting company" and is not required to provide quantitative market risk disclosures.
• Forward-Looking Statements: Management cautions that future results may differ materially from anticipated revenues due to market conditions, capital raising success, and regulatory factors.

Investor Verification Checklist

• Customer Concentration: Verify the creditworthiness and payment status of the two customers comprising over 50% of gross receivables.
• Revenue Sustainability: Assess whether the 19.5% revenue growth is sustainable given the decline in U.S. sales and the heavy reliance on Asian markets.
• One-Time Items: Confirm the impact of the $140,400 Therapeutic Drug Recovery Act funds on operating cash flow and whether this is a recurring revenue stream.
• Debt Covenants: Review the terms of the $400,000 line of credit and the equipment loan to ensure compliance with covenants, particularly the requirement to maintain a zero balance on the line for 30 consecutive days annually.
• Inventory Levels: Monitor inventory levels ($1.74M) relative to sales velocity to ensure no obsolescence risks, especially given the shift in product mix.